Abstract 1194P
Background
Neuroendocrine tumors of the appendix are typically detected incidentally during appendectomy. A recent study reported no cases of metachronous metastases among patients with primary tumors <2cm, regardless of lymph node status or referral for completion hemicolectomy. However, questions persist regarding the possibility of metastases developing decades after surgery, particularly since appendiceal NETs are frequently diagnosed in young adults and children.We therefore sought to evaluate patients with metastatic appendiceal NETs to assess whether any had been diagnosed previously with an early stage appendiceal NET.
Methods
We analyzed a large institutional neuroendocrine tumor database to identify appendiceal NETs of all stages and ascertain whether any patients with localized tumors developed metastases, and whether any with metastatic disease had originally presented with an early-stage tumor.
Results
Out of over 5,000 patients seen in the neuroendocrine tumor clinic between 2008 and 2022, 95 were diagnosed with an appendiceal NET. Of these, only 6 patients (approximately 0.1% of total NET population) had stage 4 metastases, all diagnosed synchronously at time of initial diagnosis. All 6 patients had peritoneal disease. No patient with earlier-stage disease developed distant metastases.
Conclusions
Metastatic appendiceal NETs are exceptionally rare with a tendency to metastasize within the peritoneum. In all cases of stage 4 disease, metastases were observed at time of diagnosis. Our data provide further validation for the proposition that small local appendiceal NETs resected during appendectomy require no further surgery or surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Strosberg: Financial Interests, Personal, Speaker’s Bureau: Ipsen, Tersera; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13